Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.

All peptides
DermatologyResearch Phase

Melitane (Acetyl Hexapeptide-1)

Topical
Written by Peptide Association Editorial TeamMedically reviewed by Ian Justl Ellis, MD, CPTLast reviewed Editorial policy

Overview

Acetyl Hexapeptide-1 is a synthetic hexapeptide designed to stimulate melanin synthesis by acting as an agonist at melanocortin-1 receptors on melanocytes. The acetyl modification is intended to improve peptide stability and cellular permeability.

Mechanism of Action

Its therapeutic rationale is to promote tanning and photoprotection through increased melanogenesis, potentially offering a biomimetic alternative to UV exposure for pigmentation enhancement.

Research Summary & Key Findings

In vitro studies have shown increased tyrosinase activity and melanin content in melanocyte cultures. Small-scale human studies have reported modest increases in skin pigmentation without UV exposure, though safety data regarding long-term use and effects on melanocytic proliferation are limited.

Clinical Status

Research Phase

Melitane (Acetyl Hexapeptide-1) is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.

Administration Routes

Topical

References

Primary literature

Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.

Related Peptides in Dermatology

No lawful pathway today

Melitane (Acetyl Hexapeptide-1) is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.

Tell me if the status changes

One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.